"Cipla Medpro creates and maintains strong brands by ensuring a robust pipeline of novel, high potential products, and by providing ongoing promotions and market support," adds Gerber. "These efforts support Cipla Medpro in growing its market share in the South African market."
The company enjoys leadership in customer value by offering competitive pricing of high quality products. It has ensured that its production plant meets international Pharmaceutical Inspection Convention Standards and the quality of its products is benchmarked against international standards.
Efficient distribution and ongoing marketing support has ensured that the Cipla Medpro brand is associated with efficiency and reliability. Furthermore, Cipla Medpro creates customer value by addressing the key challenges within the South African market.
"An example of this is its diversification into niche markets, such as the planned launch of its oncology division in 2010, which will address this market segment's need for affordable medicines," explains Gerber. "By supplying pharmaceuticals of the highest quality at affordable prices and addressing the growing needs of South African healthcare, Cipla Medpro has gained a competitive advantage."
Jerome Smith, Cipla Medpro South Africa Ltd CEO said he was extremely proud of Frost & Sullivan's acknowledgment of the company's efforts.
"Our comprehensive portfolio of scientifically advanced medicines, strong pipeline, swift registrations and numerous first to market launches including, recently, the first Biosimilar human insulin, are testimony of our commitment to one guiding ethos, that access to world class, yet affordable medicines is a right, not a luxury.
"The local pharmaceutical market is a competitive, regulated one however the growth potential is immense. In 2008, generics accounted for j
|Copyright©2009 PR Newswire.|
All rights reserved